Bacil Pharma [BACPHAR] vs Innova Captab [INNOVACAP] Detailed Stock Comparison

Bacil Pharma Ltd.

BSE
Loading...

Innova Captab Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Bacil Pharma Ltd. wins in 4 metrics, Innova Captab Ltd. wins in 12 metrics, with 1 ties. Innova Captab Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Bacil Pharma Ltd. Innova Captab Ltd. Better
P/E Ratio (TTM) 118.00 31.20 Innova Captab Ltd.
Price-to-Book Ratio 3.09 4.05 Bacil Pharma Ltd.
Debt-to-Equity Ratio 0.00 32.95 Tie
PEG Ratio -0.91 1.33 Innova Captab Ltd.
EV/EBITDA -312.09 20.49 Innova Captab Ltd.
Profit Margin (TTM) 134.64% 8.85% Bacil Pharma Ltd.
Operating Margin (TTM) -39.22% 12.88% Innova Captab Ltd.
EBITDA Margin (TTM) N/A 12.88% N/A
Return on Equity 1.59% 13.37% Innova Captab Ltd.
Return on Assets (TTM) 1.58% 8.12% Innova Captab Ltd.
Free Cash Flow (TTM) $4.01M $-1.09B Bacil Pharma Ltd.
Dividend Yield N/A 0.30% N/A
1-Year Return 10.61% 3.87% Bacil Pharma Ltd.
Price-to-Sales Ratio (TTM) 154.56 2.76 Innova Captab Ltd.
Enterprise Value $754.34M $43.41B Innova Captab Ltd.
EV/Revenue Ratio 137.68 2.90 Innova Captab Ltd.
Gross Profit Margin (TTM) N/A 35.19% N/A
Revenue per Share (TTM) $0 $262 Innova Captab Ltd.
Earnings per Share (Diluted) $0.50 $23.16 Innova Captab Ltd.
Beta (Stock Volatility) 0.55 -0.33 Innova Captab Ltd.

Bacil Pharma Ltd. vs Innova Captab Ltd. Stock Performance Analysis

Loading Price Chart...

BACPHAR
INNOVACAP

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Bacil Pharma Ltd.-9.98%-20.59%-30.97%-19.51%0.92%5.05%
Innova Captab Ltd.0.58%8.95%10.45%34.08%34.58%28.37%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Bacil Pharma Ltd.10.61%366.06%494.15%1,158.50%1,113.06%494.15%
Innova Captab Ltd.3.87%74.08%74.08%74.08%74.08%74.08%

Performance & Financial Health Analysis: Bacil Pharma Ltd. vs Innova Captab Ltd.

MetricBACPHARINNOVACAP
Market Information
Market Cap i₹804.20M₹41.43B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i5,580578,151
90 Day Avg. Volume i15,293217,693
Last Close₹39.31₹947.95
52 Week Range₹26.69 - ₹61.80₹622.00 - ₹978.00
% from 52W High-36.39%-3.07%
All-Time High₹62.56 (Dec 16, 2024)₹1,260.00 (Jan 06, 2025)
% from All-Time High-37.16%-24.77%
Growth Metrics
Quarterly Revenue GrowthN/A0.42%
Quarterly Earnings GrowthN/A0.23%
Financial Health
Profit Margin (TTM) i1.35%0.09%
Operating Margin (TTM) i-0.39%0.13%
Return on Equity (TTM) i0.02%0.13%
Debt to Equity (MRQ) i0.0032.95
Cash & Liquidity
Book Value per Share (MRQ)₹19.09₹178.28
Cash per Share (MRQ)₹1.22₹10.22
Operating Cash Flow (TTM) i₹3.94M₹282.88M
Levered Free Cash Flow (TTM) i₹4.04M₹1.28B
Dividends
Last 12-Month Dividend Yield iN/A0.30%
Last 12-Month Dividend iN/A₹2.00

Valuation & Enterprise Metrics Analysis: Bacil Pharma Ltd. vs Innova Captab Ltd.

MetricBACPHAR (Apr 24, 2026)INNOVACAP (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i118.0031.20
Forward P/E iN/A21.90
PEG Ratio i-0.911.33
Price to Sales (TTM) i154.562.76
Price to Book (MRQ) i3.094.05
Market Capitalization
Market Capitalization i₹804.20M₹41.43B
Enterprise Value i₹754.34M₹43.41B
Enterprise Value Metrics
Enterprise to Revenue i137.682.90
Enterprise to EBITDA i-312.0920.49
Risk & Other Metrics
Beta i0.55-0.33
Book Value per Share (MRQ) i₹19.09₹178.28

Financial Statements Comparison: Bacil Pharma Ltd. vs Innova Captab Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBACPHAR (2025)INNOVACAP (2025)
Revenue/Sales i012.34B
Cost of Goods Sold i08.38B
COGS % of Revenue i-67.9%
Gross Profit i03.96B
Gross Margin i-32.1%
Research & Development iN/AN/A
Operating Income (EBIT) i-1.87M1.65B
Operating Margin i-13.4%
EBITDA i-1.29M2.00B
EBITDA Margin i-16.2%
Pre-Tax Income i4.08M1.71B
Pre-Tax Income % of Revenue i-13.9%
Income Tax i34,460427.58M
Income Tax % of Revenue i-3.5%
Net Income (Profit) i4.04M1.28B
Profit Margin i-10.4%

Balance Sheet & Liquidity Metrics

MetricBACPHAR (2025)INNOVACAP (2025)
Cash & Equivalents i28.57M155.19M
Total Current Assets i29.07M7.03B
Total Current Assets % of Revenue i-57.0%
Total Current Liabilities i1.69M3.53B
Total Current Liabilities % of Revenue i-28.6%
Long-Term Debt iN/A2.45B
Long-Term Debt % of Revenue i-19.8%
Total Shareholders Equity i254.31M9.59B
Retained Earnings i114.61M4.53B
Retained Earnings % of Revenue i-36.7%
Property, Plant & Equipment iN/A442.93M

Cash Flow Statement Comparison

MetricBACPHAR (2025)INNOVACAP (2025)
Operating Cash Flow i3.94M282.88M
Operating Cash Flow % of Revenue i-2.3%
Capital Expenditures i0-1.72B
Free Cash Flow i4.01M-1.09B
FCF Margin i--8.8%
Debt Repayment iN/A-114.03M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricBACPHARINNOVACAP
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i14.35M57.22M
Float Shares i3.93M15.91M
% Held by Insiders i81.03%72.19%
% Held by Institutions i0.00%19.22%
% Held by Public i18.97%8.59%

Dividend Analysis & Yield Comparison: Bacil Pharma Ltd. vs Innova Captab Ltd.

MetricBACPHARINNOVACAP
Last 12-Month Dividend iN/A₹2.00
Last 12-Month Dividend Yield iN/A0.30%
3-Year Avg Annual Dividend iN/A₹0.67
3-Year Avg Dividend Yield iN/A0.30%
3-Year Total Dividends iN/A₹2.00
Ex-Dividend DateN/AJan 30, 2026